Fluorouracil News and Research

RSS

Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.

Sequential and combination chemotherapy equally effective in treating advanced colorectal cancer

Many patients with incurable advanced colorectal cancer could be offered a more gentle treatment strategy starting with a single chemotherapy drug, as an alternative to current standard initial combination chemotherapy, without compromising their survival.

16 Jul 2007

Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer

The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with oesophageal cancer, according to a study published last month in the Annals of Surgery.

16 Jul 2007

Fat kills cancer!

Researchers in Slovakia have been able to derive mesenchymal stem cells from human adipose, or fat, tissue and engineer them into "suicide genes" that seek out and destroy tumors like tiny homing missiles.

3 Jul 2007

Physiological differences between men and women impact colorectal cancer progression

Physiological differences between men and women may contribute to differential tumor development and progression in colon cancer patients, a study led by researchers at the University of Southern California (USC) suggests.

5 Jun 2007

New drugs to fight colon and breast cancer

A study on epithelial cell lines has allowed for the development of six new drugs to fight colon and breast cancer more effectively than other currently used drugs.

3 Jun 2007

Cancer Research Technology licenses therapeutic antibodies to Peptech

Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, today announces it has licensed rights to a panel of cancer therapeutic antibodies to Peptech Limited.

2 May 2007

Viventia Biotech announces results of Proxinium antibody in combinaton with chemotherapy and radiation

Viventia Biotech has announced results of in vitro cytotoxicity and in vivo pharmacokinetic studies conducted to evaluate the potential for combining its phase III anti-cancer antibody therapeutic, Proxinium, with first-line standard of care therapy for squamous cell carcinoma of the head & neck (SCCHN).

19 Apr 2007

ADVENTRX announces positive data from multidrug therapy with cofactor

ADVENTRX Pharmaceuticals has announced positive results from preclinical studies using a multidrug treatment regimen including ANX-510 (CoFactor) at the American Association for Cancer Research (AACR) Annual Meeting.

19 Apr 2007

New treatment option gives hope to victims of head and neck cancers

More than 640,000 people worldwide are diagnosed with head and neck cancer each year, and more than 350,000 die from the disease annually.

19 Oct 2006

FDA approves Taxotere for head and neck cancers

The Food and Drug Administration (FDA) today approved Taxotere (docetaxel) Injection Concentrate for use in combination with cisplatin and fluorouracil prior to radiotherapy for the treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN).

18 Oct 2006

Addition of gemcitabine to standard postoperative treatment increased pancreatic cancer patients' survival by 50 percent

Adding the cancer-fighting drug gemcitabine to standard therapy after surgery significantly improves survival for patients with the most common form of pancreatic cancer, according to a new multicenter study led by a University of Maryland radiation oncologist.

6 Jun 2006

Taxotere combined with standard chemotherapy improves survival in advanced head and neck cancers

The addition of docetaxel (Taxotere) to an initial chemotherapy regimen for inoperable head and neck cancers reduced mortality by nearly 30 percent over three years following treatment compared to the standard two-drug combination.

5 Jun 2006

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston.

3 May 2006

Studying the gene-expression profiles of patients with colorectal cancer might help predict their response to chemotherapy

Studying the gene-expression profiles of patients with colorectal cancer might help predict their response to chemotherapy.

15 Mar 2006

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer

A new study shows that patients whose colorectal cancer has spread to the liver who received an approach called hepatic arterial infusion (HAI) - the administration of chemotherapy directly to the liver through a pump in the abdomen - fare better than those who received traditional, intravenous chemotherapy.

1 Mar 2006

Mangafodipir appears to increase the cancer-killing ability of some chemotherapy drugs

A contrast agent currently used in magnetic resonance imaging (MRI), called mangafodipir, may increase the cancer-killing ability of some chemotherapy drugs while protecting normal cells, according to a study in the Journal of the National Cancer Institute.

21 Feb 2006

FOLFOX now treatment standard for colorectal cancer in the United States

One of the newest and most potent chemotherapies for colon cancer is as safe and effective for the elderly as it is for younger patients, based on a University of North Carolina at Chapel Hill-led data review.

16 Feb 2006

Chemotherapy is a beneficial treatment women and elderly

Although all eligible patients with stage III colon cancer should be offered adjuvant chemotherapy treatment because it improves survival, up to one-third are not, and many of these excluded patients are women and the elderly, say researchers who looked at data from more than 85,000 patients.

7 Dec 2005

Expert highlights public health problem posed by colorectal cancer

Colorectal cancer is a significant public health problem for which differing treatment regimes hold different benefits in associated efficacy, safety and tolerability, according to study findings showcased at the 13th European Cancer Conference (ECCO).

3 Nov 2005

Imiquimod and fluorouracil emerge as effective weapons for treating superficial basal cell carcinomas

Basal cell carcinoma, a type of skin cancer, affects millions of people worldwide. While traditional treatment has been surgery and radiation, topical treatments in combination with surgery are showing more promise for patients with basal cell carcinoma.

21 Jul 2005